Supply Chain

From November 2023, the Drug Supply Chain Security Act requires healthcare manufacturers, distributors, providers, and dispensers to exchange the serialized item-level product information that has been collected, standardized, and digitized. Hitting this deadline hinges on intensive collaboration between manufacturers and their supply chain partners that must begin now

Acquisition works toward addressing needs of regenerative medicine industry

Includes a 36,000-square-foot addition to Charlottetown location

Includes 100,000 square feet of controlled ambient storage

Campus will feature a CDMO, over 1,000,000 square feet of floor space

Global demand for the aforementioned month was greater than 2021, report shows

Company strives to provide essential medicines that are in low supply

Product is powered by company’s Opus platform

Reportedly provides 270 hours of independent runtime for temperature-sensitive pharma transportation

Collective project expected to enhance the manufacturing supply chain for ATMPs within the UK

Deal features $45 million for commercialization of several Big Pharma products

Acquisition expected to be finalized in April

Survey conducted by HDA reveals thought process of manufacturers, distributors, and 3PLs

EVERSANA‘s Danny Williams talks about how global channel management and 3PL has changed over the last three decades, the impact of COVID-19, and what we can expect to see in the future of the space.

Moderna, Pfizer, and BioNTech seeking FDA approval for fourth dose of their respective shots

Among benefits, Expanded Access software can reportedly help design more effective clinical trials and capture RWD

Latest report suggests a slower rate of growth and constrained capacity

New center comes in response to increasing demand for firm’s medicines

Deal expected to help expand its API production services

If given green light by European Commission, vaccine dose will be less than that of adolescents

Leslie Lotano-Saba, VP of Pharmacy Solutions at AArete, sizes up the problem and discusses the main factors driving these shortfalls, along with the class of medicines hardest hit.

GTS improvements include additional data integrity protection, greater Level 1 and 2 equipment compatibility

A chat with Cardinal Health’s Joel Wayment, who dives into what can be done to help ensure that patients receive their necessary medications, no matter the conditions

The parties are partnering up to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies

Advance purchase agreement is for up to 200 million doses of Nuvaxovid

Discussions will revolve around fortifying the pharma supply chain

Turnkey centers will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa

CDMO obtains both Vibalogics and Arranta Bio to increase presence in the sector

Will establish presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden

Agreement provides pharma firms with an RWD and commercialization solution